Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
9,444 total articles
Target (TGT) is trading under pressure from competitive and margin concerns, but the stock's valuation and cash flow profile make a compelling mid-term long. Entry at $111.31, stop at $103.00 and a target of $125.00 gives a favorable risk/reward while collecting a healthy 4%+ yield and exposure to improving private-label momentum.
Zepp Health (ZEPP) has gone from recovery story to credible consumer-wearables contender after a dramatic 2025 rally. Fundamentals and retail traction suggest further upside; this note lays out an actionable long with entry, stop and target and the key risks to watch.
DRSHF is an OTC counter-drone specialist trading at $2.61 with heavy short interest and increasing short-volume spikes. For disciplined traders, this setup offers a defined entry at $2.61, a tight stop at $2.10, and a mid-term target of $4.50 — a trade that profits if a short-covering rally or tactical contract news accelerates buying.
Shares of American Airlines plunged after a disappointing quarter, handing the market a rare chance to buy a major U.S. network carrier at bargain prices. With a market cap near $9.2 billion, positive free cash flow, an EV/EBITDA of ~8.2 and a FCF yield approaching 10%, the risk-reward favors a mid-term long. This piece lays out why, how to trade i…
John B. Sanfilippo & Son (JBSS) has rallied to fresh 52-week highs but the setup still favors a measured long. Q4 EPS strength, low leverage, positive free cash flow and an EV/EBITDA of ~8 give the stock an attractive risk-reward for a mid-term swing. Enter on a light pullback or at-market, place a disciplined stop under the 50-day trend, and targe…
Amazon's top-line strength masks a margin story that is deteriorating. With negative free cash flow of -$32.4B, a P/E near 34, EV/EBITDA ~29.6 and rising operating pressure in retail and advertising, the risk/reward over the next 45 trading days favors a tactical short. This trade idea lays out a clear entry, stop and target, plus catalysts and wha…
PIMCO Income Strategy Fund II (PFN) yields ~11.6% and trades near its 52-week high but still shows upside if the Fed transitions away from tightening. This trade targets price appreciation from discount tightening and carry while keeping a disciplined stop in place.
Western Digital (SanDisk brand) is at the center of AI-driven demand for high-performance storage. Strong cash generation, solid profitability (ROE 52.9%) and a supply-constrained NAND market underpin the rally, but the run-up is extreme and technicals show stretched momentum. This trade idea proposes a disciplined mid-term long with an explicit en…
Lithia's recent capital moves and acquisitions signal a shift from relentless roll-up growth toward a more mature capital allocation mix. At current levels the stock offers a low P/E and attractive upside if the company can convert acquisitions into improved margins and restore free cash flow. This trade targets a re-rating over the next 180 tradin…
Meta remains a buy today on a mix of robust profitability, accelerating AI-driven revenue growth, and a still-favorable technical setup. That said, management's planned jump in capital spending and rising Reality Labs costs compress upside and increase volatility. This trade idea targets a measured rebound toward the 52-week highs while setting a t…
Taiwan Semiconductor (TSM) sits at the center of the AI hardware boom. With ~72% pure-foundry share, $122.4B revenue in 2025 (+36% YoY), and industry-leading margins, TSM is a capital-intensive but structurally advantaged way to play hyperscaler spending. Trade plan: long at $336.88, stop $312.00, target $420.00 over a long-term (180 trading days) …
Kyocera is sitting near its 52-week high after a Q3 outperformance narrative and early-stage corporate restructuring. Fundamentals in ceramics, semiconductor packaging and building-integrated photovoltaics provide a constructive backdrop. Technicals point to strong momentum but elevated RSI argues for disciplined entry and tight risk control. We re…
Applied Digital (APLD) has been a runaway market favorite as AI hyperscalers chase customized capacity. The company offers compelling contract visibility - nearly 600 MW and a cited $16 billion lease backlog - but the stock is priced for near-perfect execution. This trade idea outlines a mid-term (45 trading days) long with a precise entry at $35.5…
Corsair (CRSR) is trading near its 52-week low on weak consumer demand, but a clear exposure to the memory cycle that AI is reigniting, plus positive free cash flow and a sub-$600M market cap, create a risk-controlled long opportunity. Entry at $5.05, stop at $4.40 and staged targets at $7.50 and $10.00 over a 180 trading-day horizon.
Costamare Bulkers (CMDB) has rallied from its 2025 lows but still trades at roughly 0.51x book and a sub-$430M market cap. The business owns 37 dry bulk vessels and manages 39 on period charters; short-term P&L noise and legacy liquidations produced a H1 2025 loss of $26.5M. Technical momentum is bullish and the risk/reward favors a mid-term long. …
Palantir's 02/02/2026 results and aggressive 2026 guidance suggest the company is entering a higher-growth phase powered by enterprise AI adoption and strategic partnerships. The stock traded up sharply, but technicals show room for additional upside. This trade idea targets a re-rating toward $200 over a 180 trading-day horizon while protecting ca…
Xeris (XERS) is showing clear commercial traction from Recorlev, with Q2 revenue near $71.5M and raised guidance. The tape and fundamentals support a mid-term long swing: entry $7.35, stop $6.25, target $9.25 over ~45 trading days. The trade balances momentum and valuation while acknowledging regulatory and execution risks.
Information Services Group (III) is a small-cap consulting and sourcing advisor with roughly $272M market cap, positive free cash flow and an attractive dividend. Continued enterprise demand for AI vendor assessments, sourcing and transformation work creates a near-term catalyst. This trade targets a re-test of the 52-week high as multiple and sent…
Chevron's recent price breakout is supported by accelerating production, wide free cash flow, a clean balance sheet, and a reliable dividend. We lay out an actionable trade: entry on confirmed breakout, a defined stop, and a near-term target that captures upside while respecting commodity volatility.
Celestica's exposure to AI infrastructure (servers, storage, networking) and the newly launched SD6300 give the stock a clear demand story even as management increases CAPEX to capture larger contracts. The trade: buy on a pullback to $285.11, stop at $260.00, target $340.00 over a mid-term 45 trading day horizon — positive catalyst-driven trade wi…
Sangoma is a small-cap Communications-as-a-Service provider trading at $4.99 with a market cap of roughly $158M and a sub-1.0 P/B. Recent operating dynamics point to a likely margin inflection from higher-margin trunking and platform revenue that the market is not fully pricing. This idea is a tactical long for a mid-term horizon (45 trading days) …
Oracle's plan to raise $45-50 billion to fund AI-focused cloud expansion has pushed the stock lower but also creates a high-conviction trade: buy into the sell-off at $160 with a long-term horizon. Technicals show oversold conditions, fundamentals show a profitable software base and strong ROE, and analysts still forecast upside. The trade accepts …
Exxon Mobil is trading near $138 while delivering industry-leading production and cash flow. With a market cap around $580B, EV/EBITDA near 9.2 and roughly $24B in free cash flow, the company offers a mix of yield, buybacks and operational optionality that buffers it against cyclical oil weakness. This trade idea lays out entry, stops and targets f…
Apple's newest window of upside is less about heavy new factories and more about software-led AI features that accelerate iPhone replacement and lift services monetization. The company prints massive free cash flow and runs a disciplined capital plan; combine that with early signs of a 23% iPhone sales surge and constructive technicals and you have…
Arbutus is a small-cap clinical-stage biotech where two near-term vectors - LNP-related litigation and follow-up imdusiran efficacy readouts - can produce outsized moves. Market capitalization sits near $844M while recent clinical data showed meaningful reductions in HBsAg. High short interest and above-average volume amplify both upside and downsi…
